Radioactive metal ions that have short half-lives are being intensely studied as pharmaceuticals. The strategy is to attach a well-designed ligand to the metal ion so that the complex very selectively aggregates in one particular type of body tissue. What properties of the ligand are important to the design of effective radiopharmaceutical therapeutic agents?